Thomas W. Stinson, III, M.D.; Decision and Order, 21720-21721 [2023-07508]
Download as PDF
21720
Federal Register / Vol. 88, No. 69 / Tuesday, April 11, 2023 / Notices
conviction.6 RFAAX 14, at 1, 3. On
August 8, 2019, the State of Ohio Board
of Pharmacy permanently revoked Emed
Medical Company’s license as a
wholesale distributor of dangerous
drugs. RFAAX 15, at 4–5; see also id. at
6–9 (May 3, 2019, letter proposing to
revoke Emed Medical Company’s
license). Finally, on December 28, 2020,
Registrants entered into settlement
agreements with the Missouri Board of
Pharmacy that placed both Emed
Medical Products’ drug distributor
permit and Med Assist Pharmacy’s
pharmacy permit on probation for three
years beginning on or about January 23,
2021. RFAAX 16, at 6, 9; RFAAX 35, at
5, 9.
In sum, despite numerous periods of
probation, suspension, and revocation
in multiple state jurisdictions,
Registrants answered ‘‘No’’ to liability
question 3 on each of the seventeen
applications they submitted prior to
issuance of the OSC. See RFAAX 18–33,
37. As such, the Agency finds that
Registrants’ answers were clearly false
because Registrants, on multiple
occasions, had their state controlled
substance registrations or licensures
placed on probation, suspended, and/or
revoked for cause.
II. Discussion
The Administrator may suspend or
revoke a registration if a registrant
materially falsified an application for
registration. 21 U.S.C. 824(a)(1). Here,
Registrants provided false information
to liability question 3 on each of their
seventeen applications—falsely
responding that they had never had a
state controlled substance registration
placed on probation, suspended, and/or
revoked for cause. See RFAAX 18–33,
37. Agency decisions have repeatedly
held that false responses to the liability
questions on an application for
registration are material. E.g., Crosby
Pharmacy and Wellness, 87 FR 21,212,
21,214 (2022); Frank Joseph Stirlacci,
M.D., 85 FR 45,229, 45,234–35 (2020).
Accordingly, the Agency finds that the
Government has established grounds to
revoke Registrants’ registrations and to
deny any pending applications of
Registrants.
lotter on DSK11XQN23PROD with NOTICES1
6 On
March 12, 2015, Eric Bailey plead guilty to
conspiracy to commit mail and wire fraud after
allowing Emed Medical Products’ license to be used
by a criminal codefendant and facilitating the
writing of funds for shipment of pharmaceuticals.
RFAAX 12, at 1, 9–10; see also RFAAX 11; RFAAX
13. In the current matter, the OSC does not allege
that Registrants’ failure to disclose this criminal
conviction in response to liability question 4 on
their various DEA applications constitutes
additional incidents of material falsification;
instead, these facts are provided as background only
and are immaterial to the Agency’s decision.
VerDate Sep<11>2014
17:45 Apr 10, 2023
Jkt 259001
III. Sanction
Where, as here, the Government has
established grounds to revoke a
registration or deny an application, the
burden shifts to the registrants to show
why they can be entrusted with the
responsibility carried by a registration.
Garret Howard Smith, M.D., 83 FR
18,882, 18,910 (2018) (citing Samuel S.
Jackson, 72 FR 23,848, 23,853 (2007)).
The issue of trust is necessarily a factdependent determination based on the
circumstances presented by the
individual registrant; therefore, the
Agency looks at factors, such as the
acceptance of responsibility and the
credibility of that acceptance as it
relates to the probability of repeat
violations or behavior and the nature of
the misconduct that forms the basis for
sanction, while also considering the
Agency’s interest in deterring similar
acts. See Arvinder Singh, M.D., 81 FR
8,247, 8,248 (2016).
Here, Registrants did not avail
themselves of the opportunity to refute
the Government’s case or demonstrate
why they can be entrusted with
registration. Moreover, Registrants
repeated their misconduct for years,
rendering it particularly egregious.
Accordingly, the Agency will order the
sanctions requested by the Government,
as contained in the Order below.
Order
Pursuant to 28 CFR 0.100(b) and the
authority vested in me by 21 U.S.C.
823(g)(1) and 824(a)(2), I hereby revoke
Emed Medical Company LLC’s DEA
Certificate of Registration No.
RE0357271 and Med Assist Pharmacy’s
DEA Certificate of Registration No.
FM2022008. Further, pursuant to 28
CFR 0.100(b) and the authority vested in
me by 21 U.S.C. 823(g)(1), I hereby deny
any pending applications of Emed
Medical Company LLC or Med Assist
Pharmacy to renew or modify their
registrations, as well as any other
pending application(s) that they may
have for addition registration in
Missouri. This Order is effective May
11, 2023.
Signing Authority
This document of the Drug
Enforcement Administration was signed
on April 4, 2023, by Administrator
Anne Milgram. That document with the
original signature and date is
maintained by DEA. For administrative
purposes only, and in compliance with
requirements of the Office of the Federal
Register, the undersigned DEA Federal
Register Liaison Officer has been
authorized to sign and submit the
document in electronic format for
PO 00000
Frm 00119
Fmt 4703
Sfmt 4703
publication, as an official document of
DEA. This administrative process in no
way alters the legal effect of this
document upon publication in the
Federal Register.
Heather Achbach,
Federal Register Liaison Officer, Drug
Enforcement Administration.
[FR Doc. 2023–07512 Filed 4–10–23; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Thomas W. Stinson, III, M.D.; Decision
and Order
On November 21, 2022, the Drug
Enforcement Administration
(hereinafter, DEA or Government)
issued an Order to Show Cause
(hereinafter, OSC) to Thomas W.
Stinson, III, M.D. (hereinafter,
Registrant). Request for Final Agency
Action (hereinafter, RFAA), Exhibit
(hereinafter, RFAAX) 2, at 1, 3. The OSC
proposed the revocation of Registrant’s
Certificate of Registration No.
AS7987348 at the registered address of
400 W Cummings Park, STE 1825,
Woburn, MA 01801. Id. at 1. The OSC
alleged that Registrant’s registration
should be revoked because Registrant is
‘‘currently without authority to handle
controlled substances in the
Commonwealth of Massachusetts, the
state in which [he is] registered with
DEA.’’ Id. at 2 (citing 21 U.S.C.
824(a)(3)).
The Agency makes the following
findings of fact based on the
uncontroverted evidence submitted by
the Government in its RFAA dated
March 6, 2023.1
Findings of Fact
On August 4, 2022, the Massachusetts
Board of Registration in Medicine
issued an Order of Temporary
Suspension that immediately suspended
Registrant’s Massachusetts medical
license. RFAAX 3, Attachment C, at 1.
Due to the suspension of Registrant’s
Massachusetts medical license, on
August 17, 2022, the Massachusetts
Drug Control Program issued a letter to
Registrant terminating Registrant’s
1 Based on the Declaration from a DEA Diversion
Investigator, the Agency finds that the
Government’s service of the OSC on Registrant was
adequate. RFAAX 3, at 2–3. Further, based on the
Government’s assertions in its RFAA, the Agency
finds that more than thirty days have passed since
Registrant was served with the OSC and Registrant
has neither requested a hearing nor submitted a
corrective action plan and therefore has waived any
such rights. RFAA, at 2–3; RFAAX 3, at 3; see also
21 CFR 1301.43 and 21 U.S.C. 824(c)(2).
E:\FR\FM\11APN1.SGM
11APN1
Federal Register / Vol. 88, No. 69 / Tuesday, April 11, 2023 / Notices
Massachusetts controlled substance
registration (hereinafter, MCSR).
RFAAX 3, Attachment D.2
According to Massachusetts online
records, of which the Agency takes
official notice, Registrant’s MCSR is
terminated.3 Massachusetts Health
Professions License Verification Site,
https://madph.mylicense.com/
verification (last visited date of
signature of this Order).4 Accordingly,
the Agency finds that Registrant is not
authorized to handle controlled
substances in Massachusetts, the state in
which he is registered with the DEA.
Discussion
Pursuant to 21 U.S.C. 824(a)(3), the
Attorney General is authorized to
suspend or revoke a registration issued
under section 823 of the Controlled
Substances Act (hereinafter, CSA)
‘‘upon a finding that the registrant . . .
has had his State license or registration
suspended . . . [or] revoked . . . by
competent State authority and is no
longer authorized by State law to engage
in the . . . dispensing of controlled
substances.’’ With respect to a
practitioner, the DEA has also long held
that the possession of authority to
dispense controlled substances under
the laws of the state in which a
practitioner engages in professional
practice is a fundamental condition for
obtaining and maintaining a
practitioner’s registration. See, e.g.,
James L. Hooper, M.D., 76 FR 71371
(2011), pet. for rev. denied, 481 F. App’x
826 (4th Cir. 2012); Frederick Marsh
lotter on DSK11XQN23PROD with NOTICES1
2 The
letter states that Registrant ‘‘is no longer
authorized to prescribe, distribute, possess,
dispense, or administer controlled substances in the
Commonwealth of Massachusetts.’’ Id. Moreover,
on February 2, 2023, the Massachusetts Board of
Registration in Medicine issued a Final Decision
and Order revoking Registrant’s Massachusetts
medical license. RFAAX 3, Attachment E, at 1, 6.
3 Under the Administrative Procedure Act, an
agency ‘‘may take official notice of facts at any stage
in a proceeding—even in the final decision.’’
United States Department of Justice, Attorney
General’s Manual on the Administrative Procedure
Act 80 (1947) (Wm. W. Gaunt & Sons, Inc., Reprint
1979). Pursuant to 5 U.S.C. 556(e), ‘‘[w]hen an
agency decision rests on official notice of a material
fact not appearing in the evidence in the record, a
party is entitled, on timely request, to an
opportunity to show the contrary.’’ Accordingly,
Registrant may dispute the Agency’s finding by
filing a properly supported motion for
reconsideration of findings of fact within fifteen
calendar days of the date of this Order. Any such
motion and response shall be filed and served by
email to the other party and to the DEA Office of
the Administrator, Drug Enforcement
Administration at dea.addo.attorneys@dea.gov.
4 Further, Registrant’s Massachusetts medical
license is revoked. Massachusetts Board of
Registration in Medicine Physician License
Verification Site, https://findmydoctor.mass.gov
(last visited date of signature of this Order).
VerDate Sep<11>2014
17:45 Apr 10, 2023
Jkt 259001
Blanton, M.D., 43 FR 27616, 27617
(1978).5
According to the Massachusetts
Controlled Substances Act, ‘‘every
person who manufactures, distributes or
dispenses, or possesses with intent to
manufacture, distribute or dispense any
controlled substance within the
commonwealth shall . . . register with
the commissioner of public health, in
accordance with his regulations . . . .’’
Mass. Gen. Laws. ch. 94C, § 7(a) (2022).
Further, ‘‘[a] prescription for a
controlled substance may be issued only
by a practitioner who is: (1) authorized
to prescribe controlled substances; and
(2) registered pursuant to the provisions
of [the Massachusetts Controlled
Substances Act].’’ Id. at § 18(a).
Here, the undisputed evidence in the
record is that Registrant lacks authority
to handle controlled substances in
Massachusetts because Registrant’s
MCSR was terminated. As already
discussed, a practitioner must hold a
valid controlled substance registration
to dispense a controlled substance in
Massachusetts. Thus, because Registrant
lacks state authority to handle
controlled substances, Registrant is not
eligible to maintain a DEA registration.
Accordingly, the Agency will order that
Registrant’s DEA registration be
revoked.
Order
Pursuant to 28 CFR 0.100(b) and the
authority vested in me by 21 U.S.C.
824(a), I hereby revoke DEA Certificate
of Registration No. AS7987348 issued to
Thomas W. Stinson, III, M.D. Further,
pursuant to 28 CFR 0.100(b) and the
authority vested in me by 21 U.S.C.
823(g)(1), I hereby deny any pending
5 This
rule derives from the text of two provisions
of the CSA. First, Congress defined the term
‘‘practitioner’’ to mean ‘‘a physician . . . or other
person licensed, registered, or otherwise permitted,
by . . . the jurisdiction in which he practices . . . ,
to distribute, dispense, . . . [or] administer . . . a
controlled substance in the course of professional
practice.’’ 21 U.S.C. 802(21). Second, in setting the
requirements for obtaining a practitioner’s
registration, Congress directed that ‘‘[t]he Attorney
General shall register practitioners . . . if the
applicant is authorized to dispense . . . controlled
substances under the laws of the State in which he
practices.’’ 21 U.S.C. 823(g)(1) (this section,
formerly § 823(f), was redesignated as part of the
Medical Marijuana and Cannabidiol Research
Expansion Act, Pub. L. 117–215, 136 Stat. 2257
(2022)). Because Congress has clearly mandated that
a practitioner possess state authority in order to be
deemed a practitioner under the CSA, the DEA has
held repeatedly that revocation of a practitioner’s
registration is the appropriate sanction whenever he
is no longer authorized to dispense controlled
substances under the laws of the state in which he
practices. See, e.g., James L. Hooper, 76 FR at
71371–72; Sheran Arden Yeates, M.D., 71 FR
39130, 39131 (2006); Dominick A. Ricci, M.D., 58
FR 51104, 51105 (1993); Bobby Watts, M.D., 53 FR
11919, 11920 (1988); Frederick Marsh Blanton, 43
FR at 27617.
PO 00000
Frm 00120
Fmt 4703
Sfmt 4703
21721
applications of Thomas W. Stinson, III,
M.D., to renew or modify this
registration, as well as any other
pending application of Thomas W.
Stinson, III, M.D., for additional
registration in Massachusetts. This
Order is effective May 11, 2023.
Signing Authority
This document of the Drug
Enforcement Administration was signed
on April 4, 2023, by Administrator
Anne Milgram. That document with the
original signature and date is
maintained by DEA. For administrative
purposes only, and in compliance with
requirements of the Office of the Federal
Register, the undersigned DEA Federal
Register Liaison Officer has been
authorized to sign and submit the
document in electronic format for
publication, as an official document of
DEA. This administrative process in no
way alters the legal effect of this
document upon publication in the
Federal Register.
Heather Achbach,
Federal Register Liaison Officer, Drug
Enforcement Administration.
[FR Doc. 2023–07508 Filed 4–10–23; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. 23–3]
Donn Bullens, J.R., N.P.; Decision and
Order
On September 7, 2022, the Drug
Enforcement Administration
(hereinafter, DEA or Government)
issued an Order to Show Cause
(hereinafter, OSC) to Donn Bullens, Jr.,
N.P. (hereinafter, Registrant). Request
for Final Agency Action (hereinafter,
RFAA), Exhibit (hereinafter, RFAAX) 2
(OSC), at 1, 3. The OSC proposed the
revocation of Registrant’s Certificate of
Registration No. MB4611744 at the
registered address of 227 Babcock
Street, Brookline, MA 02446. Id. at 1.
The OSC alleged that Registrant’s
registration should be revoked because
Registrant is ‘‘currently without
authority to handle controlled
substances in the Commonwealth of
Massachusetts, the state in which [he is]
registered with DEA.’’ Id. at 2 (citing 21
U.S.C. 824(a)(3)).
The Agency makes the following
findings of fact based on the
uncontroverted evidence submitted by
E:\FR\FM\11APN1.SGM
11APN1
Agencies
[Federal Register Volume 88, Number 69 (Tuesday, April 11, 2023)]
[Notices]
[Pages 21720-21721]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-07508]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Thomas W. Stinson, III, M.D.; Decision and Order
On November 21, 2022, the Drug Enforcement Administration
(hereinafter, DEA or Government) issued an Order to Show Cause
(hereinafter, OSC) to Thomas W. Stinson, III, M.D. (hereinafter,
Registrant). Request for Final Agency Action (hereinafter, RFAA),
Exhibit (hereinafter, RFAAX) 2, at 1, 3. The OSC proposed the
revocation of Registrant's Certificate of Registration No. AS7987348 at
the registered address of 400 W Cummings Park, STE 1825, Woburn, MA
01801. Id. at 1. The OSC alleged that Registrant's registration should
be revoked because Registrant is ``currently without authority to
handle controlled substances in the Commonwealth of Massachusetts, the
state in which [he is] registered with DEA.'' Id. at 2 (citing 21
U.S.C. 824(a)(3)).
The Agency makes the following findings of fact based on the
uncontroverted evidence submitted by the Government in its RFAA dated
March 6, 2023.\1\
---------------------------------------------------------------------------
\1\ Based on the Declaration from a DEA Diversion Investigator,
the Agency finds that the Government's service of the OSC on
Registrant was adequate. RFAAX 3, at 2-3. Further, based on the
Government's assertions in its RFAA, the Agency finds that more than
thirty days have passed since Registrant was served with the OSC and
Registrant has neither requested a hearing nor submitted a
corrective action plan and therefore has waived any such rights.
RFAA, at 2-3; RFAAX 3, at 3; see also 21 CFR 1301.43 and 21 U.S.C.
824(c)(2).
---------------------------------------------------------------------------
Findings of Fact
On August 4, 2022, the Massachusetts Board of Registration in
Medicine issued an Order of Temporary Suspension that immediately
suspended Registrant's Massachusetts medical license. RFAAX 3,
Attachment C, at 1. Due to the suspension of Registrant's Massachusetts
medical license, on August 17, 2022, the Massachusetts Drug Control
Program issued a letter to Registrant terminating Registrant's
[[Page 21721]]
Massachusetts controlled substance registration (hereinafter, MCSR).
RFAAX 3, Attachment D.\2\
---------------------------------------------------------------------------
\2\ The letter states that Registrant ``is no longer authorized
to prescribe, distribute, possess, dispense, or administer
controlled substances in the Commonwealth of Massachusetts.'' Id.
Moreover, on February 2, 2023, the Massachusetts Board of
Registration in Medicine issued a Final Decision and Order revoking
Registrant's Massachusetts medical license. RFAAX 3, Attachment E,
at 1, 6.
---------------------------------------------------------------------------
According to Massachusetts online records, of which the Agency
takes official notice, Registrant's MCSR is terminated.\3\
Massachusetts Health Professions License Verification Site, https://madph.mylicense.com/verification (last visited date of signature of
this Order).\4\ Accordingly, the Agency finds that Registrant is not
authorized to handle controlled substances in Massachusetts, the state
in which he is registered with the DEA.
---------------------------------------------------------------------------
\3\ Under the Administrative Procedure Act, an agency ``may take
official notice of facts at any stage in a proceeding--even in the
final decision.'' United States Department of Justice, Attorney
General's Manual on the Administrative Procedure Act 80 (1947) (Wm.
W. Gaunt & Sons, Inc., Reprint 1979). Pursuant to 5 U.S.C. 556(e),
``[w]hen an agency decision rests on official notice of a material
fact not appearing in the evidence in the record, a party is
entitled, on timely request, to an opportunity to show the
contrary.'' Accordingly, Registrant may dispute the Agency's finding
by filing a properly supported motion for reconsideration of
findings of fact within fifteen calendar days of the date of this
Order. Any such motion and response shall be filed and served by
email to the other party and to the DEA Office of the Administrator,
Drug Enforcement Administration at [email protected].
\4\ Further, Registrant's Massachusetts medical license is
revoked. Massachusetts Board of Registration in Medicine Physician
License Verification Site, https://findmydoctor.mass.gov (last
visited date of signature of this Order).
---------------------------------------------------------------------------
Discussion
Pursuant to 21 U.S.C. 824(a)(3), the Attorney General is authorized
to suspend or revoke a registration issued under section 823 of the
Controlled Substances Act (hereinafter, CSA) ``upon a finding that the
registrant . . . has had his State license or registration suspended .
. . [or] revoked . . . by competent State authority and is no longer
authorized by State law to engage in the . . . dispensing of controlled
substances.'' With respect to a practitioner, the DEA has also long
held that the possession of authority to dispense controlled substances
under the laws of the state in which a practitioner engages in
professional practice is a fundamental condition for obtaining and
maintaining a practitioner's registration. See, e.g., James L. Hooper,
M.D., 76 FR 71371 (2011), pet. for rev. denied, 481 F. App'x 826 (4th
Cir. 2012); Frederick Marsh Blanton, M.D., 43 FR 27616, 27617
(1978).\5\
---------------------------------------------------------------------------
\5\ This rule derives from the text of two provisions of the
CSA. First, Congress defined the term ``practitioner'' to mean ``a
physician . . . or other person licensed, registered, or otherwise
permitted, by . . . the jurisdiction in which he practices . . . ,
to distribute, dispense, . . . [or] administer . . . a controlled
substance in the course of professional practice.'' 21 U.S.C.
802(21). Second, in setting the requirements for obtaining a
practitioner's registration, Congress directed that ``[t]he Attorney
General shall register practitioners . . . if the applicant is
authorized to dispense . . . controlled substances under the laws of
the State in which he practices.'' 21 U.S.C. 823(g)(1) (this
section, formerly Sec. 823(f), was redesignated as part of the
Medical Marijuana and Cannabidiol Research Expansion Act, Pub. L.
117-215, 136 Stat. 2257 (2022)). Because Congress has clearly
mandated that a practitioner possess state authority in order to be
deemed a practitioner under the CSA, the DEA has held repeatedly
that revocation of a practitioner's registration is the appropriate
sanction whenever he is no longer authorized to dispense controlled
substances under the laws of the state in which he practices. See,
e.g., James L. Hooper, 76 FR at 71371-72; Sheran Arden Yeates, M.D.,
71 FR 39130, 39131 (2006); Dominick A. Ricci, M.D., 58 FR 51104,
51105 (1993); Bobby Watts, M.D., 53 FR 11919, 11920 (1988);
Frederick Marsh Blanton, 43 FR at 27617.
---------------------------------------------------------------------------
According to the Massachusetts Controlled Substances Act, ``every
person who manufactures, distributes or dispenses, or possesses with
intent to manufacture, distribute or dispense any controlled substance
within the commonwealth shall . . . register with the commissioner of
public health, in accordance with his regulations . . . .'' Mass. Gen.
Laws. ch. 94C, Sec. 7(a) (2022). Further, ``[a] prescription for a
controlled substance may be issued only by a practitioner who is: (1)
authorized to prescribe controlled substances; and (2) registered
pursuant to the provisions of [the Massachusetts Controlled Substances
Act].'' Id. at Sec. 18(a).
Here, the undisputed evidence in the record is that Registrant
lacks authority to handle controlled substances in Massachusetts
because Registrant's MCSR was terminated. As already discussed, a
practitioner must hold a valid controlled substance registration to
dispense a controlled substance in Massachusetts. Thus, because
Registrant lacks state authority to handle controlled substances,
Registrant is not eligible to maintain a DEA registration. Accordingly,
the Agency will order that Registrant's DEA registration be revoked.
Order
Pursuant to 28 CFR 0.100(b) and the authority vested in me by 21
U.S.C. 824(a), I hereby revoke DEA Certificate of Registration No.
AS7987348 issued to Thomas W. Stinson, III, M.D. Further, pursuant to
28 CFR 0.100(b) and the authority vested in me by 21 U.S.C. 823(g)(1),
I hereby deny any pending applications of Thomas W. Stinson, III, M.D.,
to renew or modify this registration, as well as any other pending
application of Thomas W. Stinson, III, M.D., for additional
registration in Massachusetts. This Order is effective May 11, 2023.
Signing Authority
This document of the Drug Enforcement Administration was signed on
April 4, 2023, by Administrator Anne Milgram. That document with the
original signature and date is maintained by DEA. For administrative
purposes only, and in compliance with requirements of the Office of the
Federal Register, the undersigned DEA Federal Register Liaison Officer
has been authorized to sign and submit the document in electronic
format for publication, as an official document of DEA. This
administrative process in no way alters the legal effect of this
document upon publication in the Federal Register.
Heather Achbach,
Federal Register Liaison Officer, Drug Enforcement Administration.
[FR Doc. 2023-07508 Filed 4-10-23; 8:45 am]
BILLING CODE 4410-09-P